Stem Cell Therapy for osteoarthritis and degenerative joint disease in Turkey – Istanbul
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Clinical guide to MSC therapy for osteoarthritis in Turkey: imaging, candidacy, evidence limits, alternatives, joint-specific delivery and Istanbul planning.
Evidence at a glance — Knee and joint osteoarthritis
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — including controlled studies
- Randomised trials?
- Multiple randomised trials and several meta-analyses (mostly small, short follow-up, high heterogeneity)
- Main outcomes studied
- Pain (VAS/WOMAC)
- Function and stiffness
- Cartilage thickness on MRI
- Rescue analgesic use
- Adverse events
- Long-term evidence
- Limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Supportive consideration alongside standard care
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Knee and joint osteoarthritis — PubMed
- Randomised controlled trials — Knee and joint osteoarthritis — PubMed
- Registered MSC trials — Knee and joint osteoarthritis — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
Records before recommendations
A proposed route is discussed only after diagnosis, investigations, current care and travel fitness have been reviewed.
No outcome guarantee
The evidence, uncertainty and reasons not to proceed are explained. Established care remains part of the decision.
Plan for continuity
Istanbul logistics, discharge documents and follow-up should connect with the clinician managing care at home.
A decision guide for patients comparing care
This page is for patients and families researching regenerative options for osteoarthritis and degenerative joint disease and comparing an Istanbul medical review with care available at home. It explains the evidence limits, questions that determine candidacy, reasons not to travel, protocol decisions, realistic expectations, costs and return-home follow-up.
Before considering stem cell therapy for osteoarthritis and degenerative joint disease
The key question: Which joint and pain generator is being treated, and do symptoms, examination and imaging point to a target that an injection could plausibly address?
Evidence status
Orthobiologic evidence varies by product, joint and disease stage. MSC treatment should not be described as guaranteed cartilage regrowth or a replacement for indicated surgery.
Standard care first
Exercise therapy, weight management, analgesia, injections and surgical opinion should be considered according to severity and patient goals.
What the review checks
Joint, imaging grade, alignment, instability, pain pattern, previous injections or surgery, medication and rehabilitation capacity.
When we redirect
Joint infection, acute fracture, advanced mechanical deformity, unexplained pain or a clear need for urgent surgery requires redirection.
Planning treatment in Istanbul
Confirm image-guided delivery, mobility aids, thrombosis precautions, companion needs and the rehabilitation plan after the flight home.
How are stem cell and exosome approaches discussed for osteoarthritis and degenerative joint disease?
For osteoarthritis, orthobiologic discussions focus on local joint signalling and symptom support. Evidence varies by product, joint, delivery method and disease stage; an injection cannot be assumed to regrow cartilage or correct major mechanical deformity.
The treatment target should be confirmed through symptoms, examination and imaging. Systemic MSC or exosome claims require particular scrutiny when the clinical problem is local and mechanical.
Who may be considered?
Candidacy is never decided from age or diagnosis alone. A medical review looks for a clear clinical question, stable health, appropriate prior care and goals that can be followed after return home.
- Symptoms, examination and imaging that identify a specific joint target
- A review of exercise, weight, medication, injection and surgical options
- Capacity to follow a structured rehabilitation plan after return
Who may not be suitable?
Joint infection, acute fracture, advanced mechanical deformity, unexplained pain or a clear need for urgent surgery requires redirection.
Active infection, unstable medical disease, pregnancy, active cancer treatment or inability to complete safe follow-up also require postponement, redirection or further specialist review.
How is a protocol for osteoarthritis and degenerative joint disease planned?
Route, dose, session count and stay length cannot be responsibly prescribed from a webpage. The written plan follows record review and should explain why each element is being proposed.
- 1
Records and diagnosis review
Recent specialist reports, investigations, medication and previous treatment are reviewed to confirm the clinical question and whether osteoarthritis and degenerative joint disease is stable enough for elective travel.
- 2
Product and route discussion
If an investigational option is discussed, the team should identify the cell or exosome product, source, testing, proposed route and why that route is being considered. No fixed dose or route is appropriate for every patient.
- 3
Individual written plan
Session count, timing, monitoring and supportive care are documented only after medical review. The plan should explain uncertainty, alternatives and what would cause treatment to be postponed or declined.
- 4
Discharge and follow-up handover
Patients receive product and procedure documentation, medication instructions, warning signs and a follow-up plan that can be shared with their clinician at home.
What results can realistically be expected?
The purpose of follow-up is to measure safety and agreed clinical goals—not to retrofit ordinary variation into a success claim.
- There is no guaranteed response and no promise of cure, reversal, remission, tissue regrowth or stopping established medication.
- Any goals should be condition-specific and measurable—for example function, symptoms, participation or rehabilitation tolerance—rather than a broad claim of regeneration.
- The timing of any change is uncertain. Immediate post-procedure observations, later clinical review and longer-term follow-up serve different purposes; published research cannot predict an individual outcome.
- No change, temporary symptoms or the need for further local assessment are possible outcomes and should be discussed before travel.
Why patients consider StemCell Longevita for osteoarthritis and degenerative joint disease
Patients may choose StemCell Longevita when they want an Istanbul review pathway built around records, written decisions and return-home coordination rather than a promise of results. These are the service standards to confirm during consultation:
Records are reviewed before a treatment recommendation or travel booking is requested
The medical team can explain why an enquiry may be declined or redirected
The proposed product, source, testing, route and traceability documents are identified in writing
Investigational options are distinguished from established treatment and medication is not stopped without the home clinician
The quotation separates clinical services, travel support, exclusions and potential extra costs
Discharge documents and a follow-up pathway are prepared for continuity with the home specialist
International patient journey for osteoarthritis and degenerative joint disease
Confirm image-guided delivery, mobility aids, thrombosis precautions, companion needs and the rehabilitation plan after the flight home.
- 1
Private record review
Send recent reports, imaging or test results and a current medication list. The team may request more information or advise against travel.
- 2
Written planning before booking
Confirm the proposed intervention, evidence status, exclusions, estimated stay, companion or accessibility needs, package inclusions and total quoted cost.
- 3
Assessment in Istanbul
Clinical review on arrival confirms that health status and records still support the plan. Treatment should be paused if new risks are identified.
- 4
Discharge and return home
Travel timing and support are adapted to osteoarthritis and degenerative joint disease. Warning signs, medication continuity and relevant documents are reviewed before departure.
- 5
Remote follow-up
Scheduled check-ins document safety and agreed outcomes, while the home specialist remains responsible for established disease management and urgent care.
How much does treatment for osteoarthritis and degenerative joint disease cost in Turkey?
A responsible quotation follows medical review. It should show the proposed clinical service and travel support separately enough for you to compare it with options in the UK, US, Germany or another home country.
- Condition-page prices are not quoted before records are reviewed because product, route, session structure, monitoring and travel support can differ.
- Ask for one written total showing the clinical service, laboratory or product documentation, hospital fees, tests, medication, transfers, accommodation and follow-up—and what is not included.
- Comparisons with the UK, US, Germany or another home country should compare like-for-like private services, not imply that an investigational intervention is equivalent to licensed standard care.
Frequently asked questions about osteoarthritis and degenerative joint disease
Related clinical questions
Where this page sits in the wider picture.